KeyCorp Raises ICU Medical (NASDAQ:ICUI) Price Target to $198.00

ICU Medical (NASDAQ:ICUI) had its target price boosted by KeyCorp from $147.00 to $198.00 in a research report released on Tuesday morning, Benzinga reports. KeyCorp currently has an overweight rating on the medical instruments supplier’s stock.

Several other equities analysts have also weighed in on ICUI. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Jefferies Financial Group assumed coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. Finally, Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.25.

ICU Medical Price Performance

Shares of ICUI stock opened at $180.94 on Tuesday. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of -73.85 and a beta of 0.66. The stock’s 50-day simple moving average is $170.09 and its 200-day simple moving average is $132.06.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. During the same quarter in the prior year, the company earned $1.58 EPS. ICU Medical’s quarterly revenue was up 8.6% on a year-over-year basis. As a group, equities analysts forecast that ICU Medical will post 3.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,552 shares of company stock worth $6,679,322. 6.70% of the stock is owned by corporate insiders.

Institutional Trading of ICU Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of ICU Medical by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ICU Medical by 21.7% in the second quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after acquiring an additional 55,588 shares in the last quarter. Silvercrest Asset Management Group LLC increased its position in shares of ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after acquiring an additional 145,485 shares during the period. Bank of New York Mellon Corp raised its stake in shares of ICU Medical by 11.5% in the second quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock valued at $25,710,000 after acquiring an additional 22,310 shares in the last quarter. Finally, Federated Hermes Inc. boosted its holdings in ICU Medical by 9.3% in the second quarter. Federated Hermes Inc. now owns 215,808 shares of the medical instruments supplier’s stock valued at $25,627,000 after purchasing an additional 18,301 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.